Leqembi Iqlik Recognized for Innovation in Healthcare
In a remarkable achievement, BioArctic AB's partner Eisai has announced that Leqembi Iqlik (lecanemab-irmb), a new subcutaneous autoinjector formulation designed for Alzheimer’s disease treatment, has been honored by TIME as one of the 'Best Inventions of 2025' in the Medical and Healthcare category.
TIME's esteemed annual list celebrates 300 groundbreaking innovations that are making a significant impact on people's lives. The 2025 list was compiled after an exhaustive evaluation process, which involved nominations from TIME editors and correspondents worldwide, alongside a public application system. This year, particular emphasis was placed on the fields of healthcare and artificial intelligence. Each nominated innovation was assessed based on originality, efficacy, ambition, and its potential impact on society.
The Journey Behind Leqembi
Leqembi was developed through a collaborative effort between BioArctic and Eisai, grounded in the pioneering work of Professor Lars Lannfelt who discovered the Arctic mutation related to Alzheimer’s disease. Eisai holds responsibility for the clinical development, market approval applications, and overall commercialization of Leqembi aimed at halting the progression of Alzheimer's.
Currently, BioArctic has the right to distribute Leqembi in the Nordic market, and both companies are gearing up for a strategic joint rollout in this region. This collaboration has been integral to the introduction of Leqembi, and it's being recognized for its innovation in approaching Alzheimer’s therapy.
Key Insights on Alzheimer's Disease Treatment
Globally, lecanemab has received regulatory approval in 50 countries, including the United States and various European nations, to treat patients with early stages of Alzheimer's disease, characterized by Mild Cognitive Impairment (MCI) or mild dementia. The treatment method using Leqembi Iqlik™ has also been approved in the U.S. for maintenance dosing, which allows patients to administer the medication through a subcutaneous injection after an initial period of intravenous maintenance. This is a notable step forward as we enter an era where more easy-to-use delivery systems are being embraced in pharmaceuticals.
Clinical Trials and Ongoing Research
The Phase 3 AHEAD 3-45 clinical study has been a significant initiative, examining lecanemab in individuals diagnosed with preclinical Alzheimer's disease. AHEAD 3-45 is a four-year research project executed as a public-private partnership, demonstrating a commitment to advancing our understanding of Alzheimer’s through rigorous scientific inquiry. This landmark study fully recruited its participants recently, highlighting both the urgency and the community's interest in effective Alzheimer's treatments.
Another key clinical study, the Tau NexGen study, focuses on individuals with Dominantly Inherited Alzheimer's Disease (DIAD) and incorporates lecanemab as its primary anti-amyloid therapy. By delving deeper into significant biomarkers and unique patient profiles, these research endeavors aim at refining treatment protocols and improving patient outcomes.
Collaboration Between BioArctic and Eisai
Since 2005, BioArctic has maintained a strong partnership with Eisai, focusing on the advancement and commercialization of innovative therapies for Alzheimer's disease. Over the years, numerous agreements have been secured, including the pivotal Development and Commercialization Agreement for the lecanemab antibody and the subsequent agreements for additional treatments.
This strategic collaboration has enabled BioArctic to leverage Eisai’s extensive resources for clinical development while retaining the rights to commercialize products in the Nordic countries. Importantly, BioArctic incurs no development costs for lecanemab, instead benefiting financially from regulatory approvals, milestone payments, and a share of global sales royalties.
BioArctic's Vision for the Future
BioArctic, a researcher-focused biopharmaceutical company based in Sweden, is dedicated to creating innovative therapies aimed at delaying or halting the advancement of neurodegenerative diseases. In addition to Leqembi, the company is actively pursuing research on other debilitating conditions, including Parkinson's disease and ALS. Utilizing their proprietary BrainTransporter™ technology, BioArctic holds the potential to revolutionize how treatments are administered to the brain, significantly increasing their effectiveness.
As BioArctic continues to push boundaries in pharmaceutical research and development, their innovative spirit and collaborative approach with Eisai place them well for future successes in the fight against Alzheimer’s disease and other neurodegenerative conditions.
Frequently Asked Questions
What is Leqembi Iqlik?
Leqembi Iqlik is a subcutaneous autoinjector formulation of lecanemab aimed at treating Alzheimer’s disease, recognized for its innovation in 2025.
Who developed Leqembi?
Leqembi was developed in partnership between BioArctic AB and Eisai, building on groundbreaking research in Alzheimer’s treatment.
What impact does Leqembi have on Alzheimer’s?
Leqembi has been shown to slow the progression of Alzheimer’s disease in patients with early-stage symptoms, improving overall quality of life.
How is Leqembi administered?
Leqembi Iqlik is administered through a subcutaneous injection, which is convenient for patients to use.
Where is Leqembi approved for use?
Leqembi is approved in over 50 countries, including the United States and various European nations, for early Alzheimer’s treatment.
